Appetite suppressants and pulmonary hypertension

N F Voelkel

Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver, Colorado, USA

Introductory article

Appetite-suppressant drugs and the risk of primary pulmonary hypertension

L Abenhaim, Y Moride, F Brenot, S Rich, J Binichou, X Kurz, T Higenbottam, C Oakley, E Wouters, M Aubier, G Simonneau, B Begaud for the International Primary Pulmonary Hypertension Study Group

Background. Recently in France, primary pulmonary hypertension developed in a cluster of patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. Methods. In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients’ sex and age. Results. The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used for a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. Conclusions. The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since the use of anorexic drugs is expected to increase in the near future. (N Engl J Med 1996;335: 609–16)

Primary pulmonary hypertension (PPH), also called unexplained pulmonary hypertension, is a rare disease with at least three different recognised histological presentations,3 of which the so-called plexogenic arteriopathy is the most commonly encountered. The disease occurs with a predominance in young women, but incidence peaks have been noted also in children and in a geriatric population.4 PPH is clinically characterised by non-specific symptoms of dyspnoea or cough and therefore is quite often initially misdiagnosed. Occasionally the first clinical presentation is with signs of right heart failure. The median survival after diagnosis of PPH has been estimated to be 2.8 years.5 Thus, in many patients the disease takes a rapidly progressive very malignant course.

In recent years associations of plexogenic pulmonary arteriopathy have been found with portal hypertension6 and with AIDS.7 Until 1993 when Brenot and coworkers8 published their observations entitled Primary pulmonary hypertension and fenfluramine use, the historical context of appetite depressants and their possible role as pulmonary hypertension-inducing drugs had been nearly forgotten. This was particularly apparent in a number of contemporary reviews of pulmonary artery hypertension where the potential aetiological role of anorexigen was not mentioned.9

The introductory article10 reminds us that there is a recognised association between the intake of certain appetite-suppressant drugs and the development of PPH.11 As stated, PPH is a rare disease and its incidence in any population group where an unusually high prevalence has been established – for example, in patients with liver cirrhosis and portal hypertension or patients with AIDS – is still rather small. The most likely explanation is a low prevalence of a “pulmonary hypertension gene” or of a constellation of genetic factors. Given such a low prevalence of genetic predisposition, any trigger or expression factor will raise the number of patients with PPH to only a small extent. The introductory article by Abenhaim et al describes the first prospective study which attempts to estimate the relative risk for the development of PPH from anorexigen use. Prior to this multinational European study there had
been isolated case reports which strongly indicated that anorexigen intake can be associated causally with PPH. Usually such association can be claimed when a patient develops unexplained pulmonary hypertension in close temporal relation to anorexigen use and when no other drugs are involved. Analysis of the data collected for the primary pulmonary hypertension registry of the US National Institutes of Health showed that 5% of the patients with PPH had a history of anorexigen use, and Bresn et al found that, among their 125 cases of PPH, 14% had a history of anorexigen use (25% of all their female patients). Based on these data, it is not likely that anorexigen use is currently the overwhelming cause of PPH, but if anorexigen use continues to increase, it is likely to become an increasingly important cause of PPH.

For the prospective International Primary Pulmonary Hypertension Study (IPPHS) Group, 35 centres in France, Belgium, the Netherlands, and the UK agreed to participate and to report cases of PPH diagnosed between September 1992 and September 1994. A total of 95 patients with PPH were identified, 64 of whom had been reported by French centres. Definite use of anorexigen had been reported by 30 of the 95 patients with PPH but by only 26 of 355 controls. Although the study was international in design, the data largely represented the French experience. Perhaps the most striking finding of the IPPHS was that roughly 12% of the patients with PPH had taken anorexigen for 12 months or longer (compared with 0.6% in the control group).

Anorexigen and PPH: the historical context

Several medical centres in Switzerland, Austria, and Germany registered an increased incidence of severe pulmonary hypertension beginning in 1967. Roughly 18 months after the anorexigen Mencol (aminorex fumarate) had been released in these three countries; by 1970 150 cases of PPH associated with anorexigen use had been reported. The 1985 review by Gurtner concluded that altogether 582 cases of anorexigen-induced PPH had been reported. The early experience with this epidemic in Vienna (Fig 1) illustrates the latency period between the time of introduction of the drug and the time when an increased incidence of PPH was recognised (the drug had been released in December 1965). Although the drug was taken off the market in November 1968, cases of anorexigen-induced PPH were diagnosed for several years thereafter (box).

Symptoms consistent with PPH occurred 9–14 months after the start of the anorexigen treatment, approximately one per 1000 anorexigen users developed PPH, and the lesions of anorexigen-induced PPH were histologically indistinguishable from those recognised in sporadic cases of PPH. Gurtner followed 71 patients with anorexigen-induced PPH and found that 34 patients had died (with a median survival of 3.5 years). There was no clearcut relationship between the amount of the drug taken and mortality, but the risk of developing anorexigen-induced PPH increased with increased drug intake. Attempts to induce pulmonary hypertension by feeding anorexigen to rodents, dogs, and cattle failed, which would not be surprising if there is a specific human genetic susceptibility. The retrospective data analysis of the anorexigen epidemic also showed that approximately 10% of the patients with PPH had used anorexigen in combination with chlorphenetermine, phenformin, or amphetamine.

Since the anorexigen epidemic, sporadic cases of PPH related to the use of fenfluramine or phenformin have been reported. Aminorex released December 1965

Report on 21 aminorex-PPH patients

Epidemiology of aminorex-PPH

First report of fenfluramine-PPH

Aminorex-PPH related; report on 582 cases

Fenfluramine retrospective data

Dexfenfluramine prospective study

Bresn (1993)

Gurtner (1970)

Douglas (1981)

Gurtner (1985)

Voelkel

Figure 1 Graph showing the increase in the incidence of primary pulmonary hypertension (particularly in women) with a latency period following introduction of the appetite suppressant. Aminorex was released in December 1965. The drug was taken off the market in November 1968. Reproduced with permission from reference 15.

Anorexigen-associated pulmonary hypertension: the pharmacological context

The exact pathogenetic events leading to the manifestation of PPH are still unknown. It appears, however, that for the anorexigen-associated cases of PPH, 5-hydroxytryptamine (5-HT, serotonin) might be a common denominator. Figure 2 shows the structures of some of the anorexigenes, including aminorex, and also the frequently used antidepressant agents such as sertraline hydrochloride and fluoxetine hydrochloride. All of these agents release 5-HT from storage sites or inhibit uptake of 5-HT, or both. Although aminorex resembles amphetamine and has been shown to release norepinephrine (norepinephrine), aminorex also releases 5-HT. Gahl and coworkers found no increase in levels of metabolites of 5-HT in the urine of patients with aminorex-induced PPH. However, these measurements were conducted many months after the anorexigen intake. Nevertheless, a unifying hypothesis operating with a 5-HT paradigm may be justified at the present time. Herve and coworkers reported the case history of a patient with PPH and a platelet storage disorder and, more recently, described the plasma 5-HT levels in patients with PPH. Of great interest is their finding that, in their patients with PPH (some of whom had taken anorexigen), there was an increase in plasma 5-HT levels and an increased release of 5-HT from the platelets. Moreover, this increase in plasma levels of 5-
Appetite suppressants and pulmonary hypertension

HT persisted in those patients who had received lung transplantation. If this finding of raised levels of 5-HT in patients with PPH can be confirmed in other populations with PPH, it would be tempting to speculate that agents which alter the metabolism of 5-HT could be trigger factors for PPH (figs 3 and 4). It is clear from experimental data that 5-HT does, indeed, cause pulmonary vasoconstriction and produces both hyperplasia and hypertrophy of isolated cultured pulmonary artery smooth muscle cells. This proliferative effect of 5-HT is apparently transduced through the 5-HT2 receptor. However, the relationship between alteration in 5-HT metabolism and PPH is probably more complex, as evidenced by the absence of reports of a relationship between the chronic intake of antidepressants such as fluoxetine hydrochloride (a very widely used drug) and PPH. However, in our centre we have recently diagnosed PPH in a woman who had not taken anorexigens but had been treated for her depression with sertraline hydrochloride (unpublished observation).

Figure 2 Chemical structures of 5-hydroxytryptamine (5-HT, serotonin) and 5-HT-releasing appetite suppressants or antidepressants.

Figure 3 Scheme depicting the confluence of a presently ill described genetic disposition and trigger factors in the development of primary pulmonary hypertension. It is clear that the trigger factors are of a vastly varied nature, including high blood flow or increased shear stress, viral infections, and anorexigens.

Figure 4 Scheme depicting a hypothetical sequence of events involving appetite suppressants which alter the metabolism of 5-hydroxytryptamine (5-HT) or affect release of 5-HT from platelets and mast cells. In susceptible individuals - that is, those with a genetic disposition - increased levels of 5-HT could both alter pulmonary vascular tone and also affect pulmonary vascular cell growth.
Anorexigen-associated pulmonary hypertension and obesity: risk-benefit ratio

It should be clear from the above that anorexigen can cause pulmonary hypertension. It should also be appreciated that many patients are looking for a pharmacological solution to their obesity problem. In the USA dieting and weight management are a multibillion dollar industry. Hundreds of new diet pill clinics have opened during the last year. Presently we have no good understanding of the relationship between body weight and pulmonary hypertension – apart from the well known association of the obesity/hyperventilation/polythemia syndrome and pulmonary hypertension.

Gurtner, summarising his experience of 71 patients with presumed anorexigen-induced PPH, 16 found that 50% of the patients had used aminorex while being only mildly overweight (110% of ideal body weight). While the normal incidence of PPH is about 1.2 cases per one million population/year, the risk of developing PPH for non-overweight users of dexfenfluramine has been estimated at 28 per million/year, and that for overweight users at 55 per million/year. 17 This implies that obesity might be a co-factor for the development of PPH, but there is much controversy as to whether obesity is independently related to PPH. The IPPHS data indicate that about 36% of the 95 patients with PPH had a body mass index of ≥ 30 compared with only 18.3% in the control group (the controls having been matched with the cases for age and sex only). The difference is probably explained by obese women being more likely to use anorexigens and the authors concluded that the effect of anorexigen intake on PPH “was the same whether patients had a high body mass index or not”. 18 However, obese patients are not infrequently depressed and they may also be hypoxaemic; it is not known whether hypoxaemia or the concomitant use of antidepressants in anorexigen users poses an increased risk for PPH. Experiments in dogs have shown an increase in pulmonary vascular resistance with a combination of hypoxemia and dexfenfluramine administration. 19

In 1996 about 10 million prescriptions for fenfluramine (total sales $150 million in 1996), and approximately 2.5 million prescriptions for dexfenfluramine were written in the USA. Whereas the profit margins for the diet pill clinics are apparently greater than those in the restaurant business, little concern is being expressed about the prospects of successful long term weight loss. Little is known from clinical studies about the efficacy of any of the currently prescribed anorexigens, but Weight Watchers International has advised that “people will take the drug for as long as they need to achieve their weight loss goal and they should continue to take the drug to maintain their weight loss” (May 1996).

All this is worrisome when one considers that the pharmaceutical industry does not generally screen new compounds for their potential to cause pulmonary hypertension. By contrast, drugs do not usually reach the market if they raise the systemic blood pressure. Given the uncertainty of currently available “diet pills” to cause successful long term weight loss 20-22 and the risk of developing a lethal disease, the risk-benefit ratio could be considered unacceptably high. The introductory article has lessened previous uncertainty and, as the number of anorexigen users in the USA approaches 20 million, we may soon witness a much greater incidence of PPH in that country as in Europe, anywhere from 400 to 1000 additional new cases of PPH per year.

Appetite suppressants and pulmonary hypertension

20 Gahl K, Greiser E. Erfahrungen einer klinisch-epidemiologischen stu-

21 Greiser E. Epidemiologische Untersuchungen zum Zusammenhang
zwischen AppetitzuÈglereinnahme und primaÈr vasculaÈrer pulmonaler

22 Kraupp VU. Tierexperimentelle untersuchungen zur Diagnose der

23 Green A. platelet aggregating agents and acute and chronic effects
on pulmonary and systemic hemodynamics

24 Littmann, Parwaresch MR, Sattler M, Sollier KU, Seufriedt A. The
effects of anorectic agents on the pulmonary pressure and morphology

25 Byrne-Quinn E, Grover RF. Aminorex (Menocil) and amphetamine:


28 McGoon MD. Vanhoutte PM. Aggregating platelets contract isolated
canine pulmonary arteries by releasing 5-hydroxytryptamine. J Clin
Invest 1984; 74:826–33.

29 Lee S-L, Wang WW, Fanburg BL. Serotonin produces both acute and chronic effects on pulmonary and systemic hemodynamics

30 Lee S-L, Wang WW, Fanburg BL. Nitréprusside inhibits serotonin-
induced mitogenesis and hypertrophy of smooth muscle cells in culture.

31 Pitt BR, Weng W, Steve AR, Blakely RD, Reynolds I, Davies P. Serotonin
increased DNA synthesis in rat proximal and distal pulmonary vascular

32 Abenhaim L, Al-Dahash, Benichou J, Begaud B. Letter to the editor. N

33 Voelkel NF, Clarke WR, Higenbottam T. Obesity, dexfenÈuramine, and
pulmonary hypertension: a lesson not learned? Am J Respir Crit Care
Med 1997; 155:786±8.

34 Naeije R, Wauthy P, Maggiorini M, Leeman M, Delcroix M. Effect of
dexfenÈuramine on hypoxic pulmonary vasoconstriction and embolic
pulmonary hypertension in dogs. Am J Respir Crit Care Med 1995;
151:1110–16.

35 Voelkel N. Drug-induced pulmonary hypertension: must history repeat
Appetite suppressants and pulmonary hypertension

NF Voelkel

Thorax 1997 52: 63
doi: 10.1136/thx.52.2008.S63

Updated information and services can be found at:
http://thorax.bmj.com/content/52/suppl_3/63.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/